Top-Rated StocksTop-RatedNASDAQ:IDYA IDEAYA Biosciences (IDYA) Stock Price, News & Analysis $36.21 -1.16 (-3.10%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$35.80▼$37.9950-Day Range$33.29▼$43.0552-Week Range$23.41▼$47.74Volume411,233 shsAverage Volume857,504 shsMarket Capitalization$2.74 billionP/E RatioN/ADividend YieldN/APrice Target$55.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get IDEAYA Biosciences alerts: Email Address IDEAYA Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.08 Rating ScoreUpside/Downside53.8% Upside$55.70 Price TargetShort InterestBearish15.08% of Float Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment1.16Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.51) to ($3.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.09 out of 5 starsMedical Sector155th out of 910 stocksPharmaceutical Preparations Industry58th out of 426 stocks 4.5 Analyst's Opinion Consensus RatingIDEAYA Biosciences has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIDEAYA Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about IDEAYA Biosciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.08% of the float of IDEAYA Biosciences has been sold short.Short Interest Ratio / Days to CoverIDEAYA Biosciences has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in IDEAYA Biosciences has recently decreased by 0.86%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIDEAYA Biosciences does not currently pay a dividend.Dividend GrowthIDEAYA Biosciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIDEAYA Biosciences has received a 72.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for IDEAYA Biosciences is -0.78. Previous Next 2.3 News and Social Media Coverage News SentimentIDEAYA Biosciences has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for IDEAYA Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for IDYA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IDEAYA Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.50% of the stock of IDEAYA Biosciences is held by insiders.Percentage Held by Institutions98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IDEAYA Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($2.51) to ($3.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEAYA Biosciences is -18.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEAYA Biosciences is -18.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIDEAYA Biosciences has a P/B Ratio of 3.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about IDEAYA Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About IDEAYA Biosciences Stock (NASDAQ:IDYA)IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Read More IDYA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IDYA Stock News HeadlinesSeptember 7 at 1:45 AM | americanbankingnews.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 30, 2024 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 7, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.August 29, 2024 | americanbankingnews.comIDEAYA Biosciences (NASDAQ:IDYA) Price Target Cut to $58.00August 26, 2024 | prnewswire.comIDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 23, 2024 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)August 14, 2024 | ca.finance.yahoo.comIDYA Jan 2025 45.000 callAugust 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for IDEAYA Biosciences Amid Promising Developments and Pipeline ExpansionSeptember 7, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.August 11, 2024 | finance.yahoo.comNews Flash: 13 Analysts Think IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Earnings Are Under ThreatAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for IDEAYA Biosciences Amidst Strategic Advancements and Robust Pipeline DevelopmentAugust 8, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)August 6, 2024 | markets.businessinsider.comIDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q2 2024August 6, 2024 | prnewswire.comIDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdateJuly 31, 2024 | finanznachrichten.deBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTDJuly 31, 2024 | prnewswire.comIDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with BiocytogenJuly 29, 2024 | prnewswire.comIDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations EventJuly 11, 2024 | prnewswire.comIDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesSee More Headlines Receive IDYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IDYA CUSIPN/A CIK1676725 Webwww.ideayabio.com Phone(650) 443-6209FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$55.70 High Stock Price Target$66.00 Low Stock Price Target$44.00 Potential Upside/Downside+53.8%Consensus RatingBuy Rating Score (0-4)3.08 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,960,000.00 Net Margins-483.05% Pretax Margin-1,285.34% Return on Equity-20.52% Return on Assets-19.73% Debt Debt-to-Equity RatioN/A Current Ratio17.50 Quick Ratio17.50 Sales & Book Value Annual Sales$11.96 million Price / Sales229.13 Cash FlowN/A Price / Cash FlowN/A Book Value$11.03 per share Price / Book3.28Miscellaneous Outstanding Shares75,687,000Free Float73,038,000Market Cap$2.74 billion OptionableOptionable Beta0.84 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Yujiro S. Hata (Age 50)President, CEO & Director Comp: $912kMr. Andres Ruiz Briseno CPA (Age 38)Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations Comp: $485.12kDr. Michael A. White Ph.D. (Age 58)Chief Scientific Officer Comp: $661.8kMr. Jason S. Throne Esq. (Age 52)J.D., Chief Legal Officer & Company Secretary Comp: $598.8kDr. Darrin M. Beaupre M.D. (Age 57)Ph.D., Chief Medical Officer Comp: $665.58kDr. Paul A. Barsanti Ph.D.Chief Technology OfficerMr. Mick O'QuigleyChief of Staff & Clinical DevelopmentMore ExecutivesKey CompetitorsCatalyst PharmaceuticalsNASDAQ:CPRXOsmotica PharmaceuticalsNASDAQ:OSMTSyros PharmaceuticalsNASDAQ:SYRSCue BiopharmaNASDAQ:CUETherapeuticsMDNASDAQ:TXMDView All CompetitorsInsiders & InstitutionsDriehaus Capital Management LLCSold 4,807 shares on 8/16/2024Ownership: 0.578%Algert Global LLCSold 24,193 shares on 8/16/2024Ownership: 0.017%The Manufacturers Life Insurance Company Sold 7,137 shares on 8/15/2024Ownership: 0.138%Scientech Research LLCBought 21,714 shares on 8/15/2024Ownership: 0.037%AQR Capital Management LLCSold 1,264 shares on 8/15/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions IDYA Stock Analysis - Frequently Asked Questions How have IDYA shares performed this year? IDEAYA Biosciences' stock was trading at $35.58 on January 1st, 2024. Since then, IDYA stock has increased by 1.8% and is now trading at $36.21. View the best growth stocks for 2024 here. How were IDEAYA Biosciences' earnings last quarter? IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by $0.14. IDEAYA Biosciences had a negative trailing twelve-month return on equity of 20.52% and a negative net margin of 483.05%. When did IDEAYA Biosciences IPO? IDEAYA Biosciences (IDYA) raised $70 million in an IPO on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO. Who are IDEAYA Biosciences' major shareholders? Top institutional shareholders of IDEAYA Biosciences include Federated Hermes Inc. (6.42%), Deerfield Management Company L.P. Series C (2.77%), Logos Global Management LP (2.25%) and Fiera Capital Corp (1.76%). Insiders that own company stock include Yujiro S Hata, Briseno Andres Ruiz, Paul A Stone, Michael Anthony White, Jason Throne and Michael P Dillon. View institutional ownership trends. How do I buy shares of IDEAYA Biosciences? Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of IDEAYA Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA) and Xeris Biopharma (XERS). This page (NASDAQ:IDYA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.